The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summary

• Published in: Rheumatology (Oxford, England) Vol. 63; no. 11; pp. 2948 - 2955
• Main Authors: Denton, Christopher P, De Lorenzis, Enrico, Roblin, Elen, Goldman, Nina, Alcacer-Pitarch, Begonya, Blamont, Emma, Buch, Maya H, Carulli, Maresa, Cotton, Caroline, Del Galdo, Francesco, Derrett-Smith, Emma, Douglas, Karen, Farrington, Sue, Fligelstone, Kim, Gompels, Luke, Griffiths, Bridget, Herrick, Ariane, Hughes, Michael, Pain, Clare, Pantano, Georgina, Pauling, John D, Prabu, Athiveeraramapandian, O'Donoghue, Nuala, Renzoni, Elisabetta A, Royle, Jeremy, Samaranayaka, Muditha, Spierings, Julia, Tynan, Aoife, Warburton, Louise, Ong, Voon H
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 11.09.2024
• Subjects: Bsr Guidelines; systemic sclerosis; interstitial lung disease; management; scleroderma; guideline
• ISSN: 1462-0324; 1462-0332; 1462-0332
• DOI: 10.1093/rheumatology/keae390

This guideline was developed according to the British Society for Rheumatology Guidelines Protocol by a Guideline Development Group comprising healthcare professionals with expertise in SSc and people with lived experience, as well as patient organization representatives. It is an update of the previous 2015 SSc guideline. The recommendations were developed and agreed by the group and are underpinned by published evidence, assessed by systematic literature review and reinforced by collective expert opinion of the group. It considers all aspects of SSc including general management, treatment of organ-based complications, including cardiopulmonary, renal and gastrointestinal tract manifestations, as well as broader impact of disease. Whilst it is focused on adults with SSc we expect that the guideline will be relevant to people of all ages and expert input and review by paediatric rheumatologists and other relevant specialists considered where the guideline was, or may not be, applicable to young people with SSc and juvenile-onset disease. In addition to providing guidance on disease assessment and management the full guideline also considers service organization within the National Health Service and future approaches to audit of the guideline. The lay summary that accompanies this abstract can be found in Supplemental information 1.